Lv1
28 积分 2023-04-03 加入
Cell-penetrating peptides for therapeutic applications: emerging design strategies and future directions
14天前
已完结
The case for cell-penetrating peptides
14天前
已完结
Intranasal delivery of glucagon-like peptide-1 to the brain for obesity treatment: opportunities and challenges
1个月前
已完结
The evolution of the obesity drug market
1个月前
已完结
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
1个月前
已完结
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
1个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
1个月前
已完结
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
2个月前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
2个月前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
3个月前
已完结
皖公网安备34019202002308
